Understanding biological rationale for specific activity of CDK1 and CDK2 as a prognostic marker of breast cancer recurrence

被引：0
|
作者：
Shibayama, Masaki
Numada, Shigehiro
Matsushima, Tomoko
Nakayama, Satoshi
Kiniwa, Tadashi
Harada, Amane
Kim, Seung
Shimomura, Atsushi
Noguchi, Shinzaburo
Ishihara, Hideki
机构：
[1] Sysmex Corp, Kobe, Hyogo, Japan
[2] Osaka Univ, Osaka, Japan
来源：
CANCER RESEARCH | 2009年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5556
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Determination of the specific activity of CDK1 and CDK2 as a novel prognostic indicator for early breast cancer
    Kim, S. J.
    Nakayama, S.
    Miyoshi, Y.
    Taguchi, T.
    Tamaki, Y.
    Matsushima, T.
    Torikoshi, Y.
    Tanaka, S.
    Yoshida, T.
    Ishihara, H.
    Noguchi, S.
    ANNALS OF ONCOLOGY, 2008, 19 (01) : 68 - 72
  • [2] CDK2 and CDK1 specific activities: A novel prognostic indicator in early breast cancer
    Kim, S.
    Masuda, N.
    Inaji, H.
    Yoshidome, K.
    Tsujimoto, M.
    Akiyama, F.
    Ishihara, H.
    Hortobagyi, G. N.
    Ueno, N. T.
    Noguchi, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] CDK1 AND CDK2 ACTIVITY IS A STRONG PREDICTOR OF RENAL CELL CANCER RECURRENCE
    Hongo, F.
    Takaha, N.
    Kimura, Y.
    Nakamura, T.
    Mikami, K.
    Nakayama, S.
    Matsushima, T.
    Ishihara, H.
    Sakai, T.
    Miki, T.
    EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 138 - 139
  • [4] Use of CDK1 and CDK2 activity to predict renal cell cancer recurrence
    Hongo, F.
    Takaha, N.
    Kimura, Y.
    Nakamura, T.
    Mikami, K.
    Nakayama, S.
    Matsushima, T.
    Ishihara, H.
    Sakai, T.
    Miki, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [5] CDK1 and CDK2 activity is a strong predictor of renal cell cancer recurrence
    Hongo, Fumiya
    Takaha, Natsuki
    Kimura, Yasunori
    Nakamura, Terukazu
    Mikami, Kazuya
    Nakayama, Satoshi
    Matsushima, Tomoko
    Ishihara, Hideki
    Sakai, Toshiyuki
    Miki, Tsuneharu
    CANCER RESEARCH, 2011, 71
  • [6] Use of CDK1 and CDK2 activity to predict renal cell cancer recurrence
    Hongo, F.
    Takaha, N.
    Kimura, Y.
    Nakamura, T.
    Mikami, K.
    Nakayama, S.
    Shibayama, M.
    Ishihara, H.
    Sakai, T.
    Miki, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] CDK1 AND CDK2 ACTIVITY IS A STRONG PREDICTOR OF RENAL CELL CANCER RECURRENCE
    Hongo, Fumiya
    Takaha, Natsuki
    Kimura, Yasunori
    Nakamura, Terukazu
    Mikami, Kazuya
    Nakayama, Satoshi
    Matsushima, Tomoko
    Ishihara, Hideaki
    Sakai, Toshiyuki
    Miki, Tsuneharu
    JOURNAL OF UROLOGY, 2011, 185 (04): : E390 - E390
  • [8] Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells
    Nakayama, Satoshi
    Torikoshi, Yasuhiro
    Takahashi, Takeshi
    Yoshida, Tomokazu
    Sudo, Tamotsu
    Matsushima, Tomoko
    Kawasaki, Yuko
    Katayama, Aya
    Gohda, Keigo
    Hortobagyi, Gabriel N.
    Noguchi, Shinzaburo
    Sakai, Toshiyuki
    Ishihara, Hideki
    Ueno, Naoto T.
    BREAST CANCER RESEARCH, 2009, 11 (01):
  • [9] Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells
    Satoshi Nakayama
    Yasuhiro Torikoshi
    Takeshi Takahashi
    Tomokazu Yoshida
    Tamotsu Sudo
    Tomoko Matsushima
    Yuko Kawasaki
    Aya Katayama
    Keigo Gohda
    Gabriel N Hortobagyi
    Shinzaburo Noguchi
    Toshiyuki Sakai
    Hideki Ishihara
    Naoto T Ueno
    Breast Cancer Research, 11
  • [10] CDK1 and CDK2 activity is a strong predictor of renal cell carcinoma recurrence
    Hongo, Fumiya
    Takaha, Natsuki
    Oishi, Masakatsu
    Ueda, Takashi
    Nakamura, Terukazu
    Naitoh, Yasuyuki
    Naya, Yoshio
    Kamoi, Kazumi
    Okihara, Koji
    Matsushima, Tomoko
    Nakayama, Satoshi
    Ishihara, Hideki
    Sakai, Toshiyuki
    Miki, Tsuneharu
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (08) : 1240 - 1246
12345